Murali Prahalad, Ph. D. is the president and CEO of Epic Sciences. Dr. Prahalad has more than 14 years of experience in technology and life science companies. Prior to joining Epic, he was formerly vice president of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across Life Technologies' research tools, clinical diagnostic and applied market portfolios. Dr. Prahalad was with Life Technologies since 2005, where he held multiple positions of increasing responsibility. His experience at Life Technologies ranged from mergers and acquisitions to inlicensing and general management, where he led large businesses that spanned genomics to cell biology. As a general manager, he had to grow revenue and profit by building stronger teams, driving innovation and managing operations for both consumable and instrument portfolios. Portfolios of note and relevance to Epic included Molecular Probes®, transfection (Lipofectamine®), custom primers and research antibodies in addition to Life Technologies imaging instrumentation (FLoID®, TALI®, Countess®) and flow cytometry platforms (Attune®). Prior to Life Technologies, he was vice president of Business Development at Sequenom, Inc. He is also proficient and literate in several languages including Japanese, French and Kannada. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology and an M.S. in medical sciences from Harvard University, and he received his B.S. with honors in cellular and molecular biology and economics from the University of Michigan.
Mr. Michael Rodriguez is the chief financial officer of Epic Sciences and has served for more than 20 years as a demonstrated cross-functional executive leader in fast growth, complex and high energy environments, with a strong financial and operational acumen in both public and private companies. He has proven success in casting tactical vision, carrying out strategic initiatives, implementing productive change and cultivating high-performance teams that increase results and profits. Before joining Epic, Mr. Rodriguez served as chief operating officer of Clarient Diagnostic Services, a GE Healthcare molecular diagnostics and laboratory services business. During this time, Mr. Rodriguez led an organization of more than 350 people in lab operations, information technology, quality assurance, project and portfolio management, facilities, materials management and environmental health and safety. Prior to his promotion to COO, he served as chief financial officer, building a best-in-class organization and guiding Clarient to profitable operations during his first year of tenure, facilitating its $587 million sale to GE Healthcare. Prior to Clarient, Mr. Rodriguez served as senior vice president and chief financial officer of Endocare (NASDAQ: ENDO), executive vice president and chief financial officer of Directfit, and senior financial capacities for Tickets.com (NASDAQ: TIXX), and EDiX Corporation. Mr. Rodriguez began his career in public accounting with Arthur Andersen & Co., and is a certified public accountant (inactive). He received an MBA from Stanford University and a B.S. in accounting from the University of Southern California. He also serves as an adjunct professor of business in the Crowell School of Business at Biola University.
Dena Marrinucci, Ph.D. is the chief scientific officer at Epic Sciences. Dr. Marrinucci is a pioneer in the circulating tumor cell (CTC) field with 10 years of experience. She received her Ph.D. from The Scripps Research Institute (TSRI), and her work at TSRI is the basis for Epic Sciences. Since receiving her Ph.D., Dr. Marrinucci has taken a senior management position at Epic leading the Companion Diagnostic (CDx) Group which is responsible for the development of CDx products co-developed with pharma partners who are leveraging Epic’s CTC platform. She also oversees all diagnostic partnering collaborations including strategy, agreements, and execution of CDx development ensuring alignment with drug development and launch. She leads multiple internal research projects as well as Clinical Operations. As study director, she is extensively involved in all on-going clinical trials from initiation of the study, to execution of experiments, to data analysis and interpretation.
Mr. Jason Adams is the vice president, business development at Epic Sciences. Prior to Epic, Mr. Adams has spent the last seven years at Ventana Medical Systems, where he has held roles with increasing responsibility. He was most recently a senior member of the companion diagnostic business development group, where he negotiated and managed alliances and partnerships with global pharmaceutical companies, including Pfizer, Seattle Genetics and Millennium, and developed high-value companion diagnostics. He also held additional roles, including as a leader of marketing, strategic planning, corporate development and scientific teams. Prior to Ventana, he was a business development manager and scientist at SGX Pharmaceuticals, an analyst at Ligand Pharmaceuticals and a research associate at Invitrogen (now Life Technologies, a brand of Thermo Fisher Scientific). He received his MBA in finance and technology management from UCLA Anderson School of Management and his B.S. in molecular and cellular biology from the University of Arizona.
Mr. Ryan Dittamore is the vice president, marketing and translational research at Epic Sciences. Mr. Dittamore is a recognized molecular diagnostics leader with a broad range of business, scientific, and medical acumen focused on developing and commercializing innovative diagnostic, prognostic and predictive tests in oncology. Mr. Dittamore is leading marketing and translational research activities to develop clinical validity and clinical utility for new products offerings addressing critical unmet medical needs in oncology. This effort includes initiation and execution of numerous oncology clinical trials with top academic and government institutes. Mr. Dittamore’s background includes a diverse set of roles inclusive of research, product development, marketing, business development, sales and global channel management. Previous to his tenure at Epic Sciences, he was director of Medical Innovation and disease lead for Genitourinary Cancers at Ventana Medical Systems (Roche Tissue Diagnostics). He holds a B.S. in biology, from University of Oregon and an MBA from University of Massachusetts, Amherst.
Pascal Bamford, Ph.D. is the vice president, product development at Epic Sciences. Dr. Bamford obtained his Ph.D. from the University of Queensland, Australia, and researched how cancer-associated changes in DNA structure, detectable in digital images, could be used to automate the process of distinguishing cervical cancer from normal cells. His early career was spent developing automated cytology imaging systems at CSSIP in Australia in collaboration with Accumed International of Chicago. He subsequently took on the role of director of Imaging at MonoGen, where he developed an all-digital, microscopy-based, cervical cancer screening product, which was recognized as the first “killer app” for the field of digital pathology. For the past five years at Ventana-Roche, Dr. Bamford has held various roles of increasing responsibility in research, digital pathology and assay development, working on fluorescence multiplexing imaging systems and driving several bright field IHC algorithm CE-IVD and 510(k) clearances. Most recently Dr. Bamford led the detection reagent development of Ventana’s next generation staining platform. He is the author of six patents and more than 18 scientific publications.
Glen Paul Freiberg, RAC is the vice president, regulatory affairs and quality assurance of Epic Sciences. Mr. Freiberg’s career began as an FDA investigator in New England, where he specialized in clinical trials, drug, medical device and diagnostic regulations. He has held positions of increasing responsibility at The Upjohn Company, The Coulter Corporation, Curtin Matheson Scientific, and Boehringer Mannheim. As vice president of clinical and regulatory affairs at Oncor, he most notably completed PMA work on DNA probes for cancer and introduced a successful FDA submission strategy using cytogenetic stains as the predicate device for DNA probes (e.g., trisomy detection). After Oncor, Mr. Freiberg was vice president at Bard Diagnostic Sciences, where he completed a PMA and two 510(k) submissions, including the first home use cancer-monitoring test, which achieved CLIA waiver. Then as vice president of regulatory, quality and government affairs at Gen-Probe, he helped in the completion of the first amplified nucleic acid tests for HIV, hepatitis and West Nile blood screening as well as for other infectious agents. He has also served as vice president of clinical, regulatory and quality at SpectraScience, and vice president of regulatory affairs and quality assurance at Eveia Medical and Alphatec Spine.